Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to$ 789 million, as reported by GSK: Q4 sales of at least ~ $260 million needed to earn$ 25 million milestone2 Q4 sales of at least ~ $610 million needed to earn$ 50 million m ...